Pharmakon Medical Research opens five active clinical trials in wound care and beyond

By AI, Created 11:33 AM UTC, May 20, 2026, /AGP/ – Pharmakon Medical Research in Palm Beach Gardens is enrolling participants in five clinical trials across wound care, pulmonology and musculoskeletal disease. The studies target chronic conditions including diabetic foot ulcers, venous leg ulcers, COPD and plantar fibromatosis, giving eligible patients access to investigational therapies and study-related care at no cost.

Why it matters: - Pharmakon Medical Research is expanding access to investigational treatments for chronic conditions that can drive pain, disability, hospitalization and amputations. - The trial portfolio includes diseases with limited treatment options, especially chronic wounds and plantar fibromatosis. - Eligible participants can receive close clinical oversight, study-related care at no cost and access to therapies not yet commercially available.

What happened: - Pharmakon Medical Research announced on April 29, 2026, that it is actively enrolling participants in five clinical trials. - The studies are open across three therapeutic areas: wound care, pulmonology and musculoskeletal disease. - Principal Investigator Orlando Cedeno, DPM, FACFAS, is leading the active studies. - The research site is based in Palm Beach Gardens, Florida.

The details: - Three wound care trials are evaluating investigational treatments for diabetic foot ulcers and venous leg ulcers. - One pulmonology trial is studying chronic obstructive pulmonary disease in patients with specific inflammatory phenotypes who remain symptomatic despite standard therapy. - One musculoskeletal trial is testing a novel approach for plantar fibromatosis. - Diabetic foot ulcers and venous leg ulcers are among the most costly and prevalent chronic wound conditions in the United States. - Those wound conditions can increase amputation risk, hospitalization and overall morbidity. - COPD remains a leading cause of death and disability nationwide. - Plantar fibromatosis can impair gait and quality of life, and non-surgical options remain limited. - Pharmakon Medical Research was founded in 2014 and runs industry-sponsored Phase 2 through Phase 4 studies. - The site works across wound care, pulmonology, regenerative medicine and musculoskeletal disease. - Pharmakon Medical Research partners with sponsors and affiliated specialty practices in Palm Beach County, including Abacoa Podiatry & Leg Vein Center and AMRI/RegenOrthoPB. - More information is available at trial information.

Between the lines: - The mix of trials suggests Pharmakon Medical Research is focusing on conditions where local access to specialty research could matter for patients who have few standard treatment options. - The wound care portfolio aligns with a high-burden area of medicine where new therapies can have outsized effects on mobility and quality of life. - Dr. Cedeno framed the enrollment push as a way to give South Florida patients access to therapies while also advancing research for future patients.

What’s next: - Pharmakon Medical Research will continue enrolling qualifying patients in the five active studies. - Patients and referring clinicians can contact the research team to ask about eligibility. - The site is expected to keep working with sponsor companies and local specialty practices as the portfolio develops.

The bottom line: - Pharmakon Medical Research is using its South Florida site to broaden trial access for chronic, hard-to-treat conditions where new options are still needed.